Browse
Browse
Home
People
Organizations
Research
Events
Capability Map
Current Opinion in Nephrology and Hypertension
Journal
Overview
Identity
Overview
Publication Venue For
Potential kidney toxicity from the antiviral drug tenofovir: New indications, new formulations, and a new prodrug
. 27:102-112.
2018
Refractory versus resistant hypertension
. 26:14-19.
2017
The role of fibroblast growth factor 23 and Klotho in uremic cardiomyopathy
. 25:314-324.
2016
Endothelin-1 and the kidney: New perspectives and recent findings
. 25:35-41.
2016
Dialysate content and risk of sudden cardiac death
. 24:557-562.
2015
Pathophysiology of the chronic kidney disease - Mineral bone disorder
. 24:303-309.
2015
Current status on the evaluation and management of the highly sensitized kidney transplant recipient
. 24:570-575.
2015
Medical management of chronic kidney disease in the renal transplant recipient
. 24:587-593.
2015
Pathogenesis of immunoglobulin A nephropathy
. 22:287-294.
2013
Nitric oxide and the A and B of endothelin of sodium homeostasis
. 22:26-31.
2013
Fibroblast growth factor 23 and the heart
. 21:369-375.
2012
Increased serum phosphate and adverse clinical outcomes: Unraveling mechanisms of disease
. 20:224-228.
2011
Mechanisms and consequences of salt sensitivity and dietary salt intake
. 20:37-43.
2011
Uric acid: A novel mediator and marker of risk in chronic kidney disease?
. 18:526-530.
2009
Tubuloglomerular feedback mechanisms in nephron segments beyond the macula densa
. 18:57-62.
2009
Renin inhibition: Should it supplant ACE inhibitors and ARBS in high risk patients?
. 17:484-490.
2008
Endothelin and NOS1/nitric oxide signaling and regulation of sodium homeostasis
. 17:70-75.
2008
Vascular stenosis: Biology and interventions
. 16:516-522.
2007
Effect of salt intake on progression of chronic kidney disease
. 15:54-60.
2006
Hormonal and cytokine effects of uric acid
. 15:30-33.
2006
Fabry disease: Diagnosis and management, with emphasis on the renal manifestations
. 14:87-95.
2005
Management of paraproteinemic renal disease
. 14:97-103.
2005
IgA nephropathy: An update
. 13:171-179.
2004
A family of calcium-permeable channels in the kidney: Distinct roles in renal calcium handling
. 11:555-561.
2002
Hormone replacement therapy and hypertension
. 11:229-235.
2002
Genetic forms of human hypertension
. 10:493-499.
2001
Interaction of syntaxins with epithelial ion channels
. 9:523-527.
2000
Renal endothelin in hypertension
. 9:157-164.
2000
Sodium transporters in health and disease
. 6:372-376.
1997
Antihypertensive therapy in the era of evidence based medical practice: What to do until the facts are in
. 5:159-161.
1996
Hypertension in postmenopausal women: Pathophysiology and management
. 4:438-442.
1995
Hypertension in women
. 4:204-207.
1995
Antihypertensive therapy in the context of total cardiovascular risk: the rational basis for therapeutic recommendations.
. 3:195-199.
1994
Neurologic consequences of hypertension and antihypertensive drug therapy.
. 3:228-235.
1994
Renal involvement in plasma cell dyscrasias.
. 2:246-252.
1993
The role of the sympathetic nervous system in hypertension.
. 2:265-273.
1993
Identity
International Standard Serial Number (issn)
1062-4821
Electronic International Standard Serial Number (eissn)
1473-6543